Sigyn Therapeutics (OTCMKTS:SIGY) Posts Quarterly Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) issued its earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, Zacks reports.

Sigyn Therapeutics Trading Up 6.4%

Shares of SIGY stock traded up $0.00 during trading on Thursday, hitting $0.03. The company’s stock had a trading volume of 4,007 shares, compared to its average volume of 95,084. The business has a fifty day moving average of $0.04 and a 200-day moving average of $0.30. Sigyn Therapeutics has a 52 week low of $0.01 and a 52 week high of $5.00. The company has a market cap of $63,500.00, a PE ratio of -0.01 and a beta of -0.08.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.